About Signature Therapeutics
Signature Therapeutics is a company based in San Carlos (United States) founded in 2004 by Steven Shafer was acquired by Ensysce in January 2015.. Signature Therapeutics has raised $10 million across 1 funding round from investors including Ensysce and Founders Fund. The company has 5 employees as of December 31, 2015.
- Headquarter San Carlos, United States
- Employees 5 as on 31 Dec, 2015
- Founders Steven Shafer
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Signature Therapeutics
Signature Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in December 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $10.0M
-
First Round
First Round
(27 Dec 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2011 | Amount | Series A - Signature Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Signature Therapeutics
Signature Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Ensysce and Founders Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and defense sectors.
|
Founded Year | Domain | Location | |
|
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Signature Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Signature Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Signature Therapeutics Comparisons
Competitors of Signature Therapeutics
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Signature Therapeutics
When was Signature Therapeutics founded?
Signature Therapeutics was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Where is Signature Therapeutics located?
Signature Therapeutics is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Who is the current CEO of Signature Therapeutics?
Wes Sterman is the current CEO of Signature Therapeutics.
Is Signature Therapeutics a funded company?
Signature Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Dec 27, 2011.
How many employees does Signature Therapeutics have?
As of Dec 31, 2015, the latest employee count at Signature Therapeutics is 5.
What does Signature Therapeutics do?
Signature Therapeutics (formerly known as PharmacoFore) is a clinical-stage biopharmaceutical company that develops prodrugs that can prevent the misuse, abuse, and overdose of prescription medications for treatment of pain and neurological disorders. The company claims its Bio-Activated Molecular Delivery (BIO-MDTM) platform eliminates the ability to abuse opioid products by the non-oral route. The companys abuse-deterrent Oxycodone, PF614, is an inactive prodrug formulation that must be digested to achieve therapeutic benefit. The company merged with Ensysce Biosciences in December 2016.
Who are Signature Therapeutics's investors?
Signature Therapeutics has 2 investors. Key investors include Ensysce, and Founders Fund.